Clinical Trial

EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)

Study acronym: EAST-1
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
GRWD0715 is an orally administered, selective inhibitor of the Endoplasmic Reticulum Aminopeptidase 1 \[ERAP1\] enzyme being explored as a potential new treatment for axial spondyloarthritis (axSpA), a long term condition caused by inflammation predominantly affecting the sacroiliac joints (SIJs) and spine.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2025-06-24; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2025-08-05
Trial Details
NCT Number NCT07047703
Lead Sponsor Grey Wolf Therapeutics
Conditions Axial Spondyloarthritis (AxSpA)
Enrollment 141 participants
Start Date 2025-07-28
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-23